JNJ-8003

JNJ-8003 is a potent and orally active non-nucleoside RSV polymerase inhibitor with an IC50 of 0.29 nM. JNJ-8003 targets the L protein polymerase complex of RSV (IC50 = 0.67 nM), and blocks the transcription and replication of the viral genome by inhibiting the activity of RNA-dependent RNA polymerase (RdRp) . JNJ-8003 displays subnanomolar activity in vitro as well as prominent efficacy in mice and a neonatal lamb models. JNJ-8003 can be used for the study of respiratory syncytial virus (RSV) [1][2].

Product Specifications

UNSPSC

12352005

Target

DNA/RNA Synthesis; RSV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/jnj-8003.html

Purity

99.84

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(N=N1)=CC2=C1C(OC)=CC(C(NC[C@](C(F)(F)F)(O)C3=CC(C(C)(C)O)=C(F)C(C4=CC=C(F)C=C4)=N3)=O)=C2

Molecular Formula

C28H25F5N4O4

Molecular Weight

576.51

References & Citations

[1]Yu X, et al. Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor. Commun Biol. 2023 Oct 21;6 (1) :1074.|[2]Grosse S, et al. Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors. J Med Chem. 2024 Aug 22;67 (16) :13723-13736.